Accustem Sciences Inc · OTC:ACUT

Accustem Sciences — Investor Presentation (December 2022)

19 slides from Accustem Sciences's investor presentation, Dec 1, 2022

  1. Slide 1: Building Better Oncology Tools

    eo = =, ee P< ACCUSTec Building Better Oncology Tools AR ACCUSTEM

  2. Slide 2: Disclaimer

    DISCLAIMER The Company has filed a registration statement on Form S-1, as amended (Registration No.: 333- ) with the Securities and Exchange Commission for the offering to which this presentation relates. Before you invest, you should read the registration statement and other documents that we have

  3. Slide 3: Company Overview

    COMPANY OVERVIEW Our mission at AccuStem is to provide novel diagnostic tools that optimize outcomes and quality of life for all patients along the continuum of oncology care, from cancer screening through treatment and monitoring. Our focus will be the commercialization of proprietary genomic tests

  4. Slide 4: AccuStem Roadmap to Commercialization

    ACCUSTEM ROADMAP TO COMMERCIALIZATION Our focus will be the commercialization of a proprietary genomic test for patients with breast cancer representing an estimated market opportunity greater than $1.3B annually TARGET CANCER ANALYTICAL CLINICAL CLINICAL CMS ASSET MARKET VALIDATION VALIDATION UTILI

  5. Slide 5: AccuStem at a Glance

    ACCUSTEM AT A GLANCE BREAST CANCER PROGRAM STEMNESS PROGRAM EFFICIENT CORPORATE EXECUTION • In-licensed StemPrintER assay from • Planning to build on current • Proven leadership team with nearly Istituto Europeo di Oncologia (IEO) research of stemness across 60 combined years of experience in differ

  6. Slide 6: The Role of "Stemness" in Cancer

    THE ROLE OF “STEMNESS” IN CANCER The cancer stem cell hypothesis is a fundamental concept in cancer biology • Essentially, all tumors arise from precursor cells that are similar to stem cells; these cancer stem cells are highly adaptable and have the ability to grow indefinitely • This hypothesis an

  7. Slide 7: Potential Utility of StemPrint Technology

    POTENTIAL UTILITY OF STEMPRINT TECHNOLOGY We believe StemPrintER is the only multi- HANNAH GILMORE, MD gene assay able to accurately assess Chief, Division of Anatomic Pathology “stemness” which may lead to enhanced patient-physician discussions and more effective treatment interventions that will i

  8. Slide 8: Breast Cancer and the StemPrintER Test

    BREAST CANCER AND THE STEMPRINTER TEST 2M+ new breast cancer diagnoses annually • No genomic tests to inform surgical approach, benefit of radiation StemPrintER is a novel 20-gene test designed to measure the "stemness" of tumors • By evaluating the underlying "stem" biology of tumors, we believe ou

  9. Slide 9: Validation of StemPrintER in Breast Cancer

    VALIDATION OF STEMPRINTER IN BREAST CANCER 1 2 N= 574 N= 644 N= 344 N= 432 StemPrintER is highly prognostic for outcomes StemPrintER outperformed the market leader- in early-stage breast cancer OncotypeDx- in the TransATAC cohort 1. Pece, et al. Ebiomedicine. 2019; 2. Pece, et al. Eur J Cancer. 2022

  10. Slide 10: Clinical Decision Making in Breast Cancer

    CLINICAL DECISION MAKING IN BREAST CANCER BIOPSY SURGERY THERAPY Clinical Questions What is the subtype of cancer? Mastectomy vs. lumpectomy? Adjuvant Chemotherapy? Is patient a candidate for NAC? Sentinel node vs. full axillary dissection? Hormone Therapy? How aggressive is the cancer? Radiation Th

  11. Slide 11: Voice of Breast Cancer Key Opinion Leader

    VOICE OF BREAST CANCER KEY OPINION LEADER “Beyond clinical factors and patient preference, we do not currently possess tools to PAT WHITWORTH, MD Breast Surgical Oncology determine the most appropriate surgical interventions, especially the need for and extent of lymph node dissection” “Knowing that

  12. Slide 12: Breast Cancer Genomics Industry

    BREAST CANCER GENOMICS INDUSTRY AccuStem Exact Sciences Agendia Hologic Myriad Genetics Veracyte Breast Cancer Product StemPrintER OncotypeDX MammaPrint Endopredict Prosigna Index Global Serviceable 798,000 562,000 562,000 562,000 562,000 562,000 Market Reimbursement (CMS) N/A $3873 $3873 $3873 $387

  13. Slide 13: AccuStem at a Glance

    ACCUSTEM AT A GLANCE BREAST CANCER PROGRAM STEMNESS PROGRAM EFFICIENT CORPORATE EXECUTION • In-licensed StemPrintER assay from • Planning to build on current • Proven leadership team with nearly Istituto Europeo di Oncologia (IEO) research of stemness across 60 combined years of experience in differ

  14. Slide 14: Opportunity in Lung Cancer

    OPPORTUNITY IN LUNG CANCER 2M+ new lung cancer diagnoses annually • No genomic tests to inform surgical approach, benefit of radiation StemPrintER may inform treatment planning in patients with early stage lung cancer • By evaluating the underlying "stem" biology of tumors, we believe our test will

  15. Slide 15: Opportunity in Prostate Cancer

    OPPORTUNITY IN PROSTATE CANCER 1.4M+ new prostate cancer diagnoses annually • No genomic tests to inform approach to definitive treatment (e.g., surgery, radiation, ablation) StemPrintER may inform treatment planning in patients with localized prostate cancer • By evaluating the underlying "stem" bi

  16. Slide 16: AccuStem at a Glance

    ACCUSTEM AT A GLANCE BREAST CANCER PROGRAM STEMNESS PROGRAM EFFICIENT CORPORATE EXECUTION • In-licensed StemPrintER assay from • Planning to build on current • Proven leadership team with nearly Istituto Europeo di Oncologia (IEO) research of stemness across 60 combined years of experience in differ

  17. Slide 17: Our Leadership Team and Approach: A Proven Track Record

    OUR LEADERSHIP TEAM AND APPROACH: A PROVEN TRACK RECORD WENDY BLOSSER, CEO JEFF FENSTERER, COO JOE FLANAGAN, CBO ü 23 years of success building organizations ü 20-year track record in long-term ü 15 years of strategic expertise with in Oncology and Women’s Health strategic planning enhanced by broad

  18. Slide 18: Corporate Board

    CORPORATE BOARD GABRIELE CERRONE WENDY BLOSSER JOHN BRANCACCIO SEAN MCDONALD WILLY SIMON Executive chairman Director Director Director Director ü Chairman and ü 25 years of success ü Over 35 years ü Experienced ü Career as an executive founder of TIZIANA launching, relaunching financial experience t

  19. Slide 19: Thank You for Your Consideration

    THANK YOU FOR YOUR CONSIDERATION [email protected] | Accustem.com

AccuStem Sciences — Investor Presentation (December 2022) on 6ix